Hepatitis B virus proteome analysis identifies apolipoprotein C1 facilitating particle production and virus entry

This study identifies apolipoprotein C1 (ApoC1) as a key host protein associated with hepatitis B virus particles that facilitates viral production and entry by modulating intracellular cholesterol levels and interacting with the HDL receptor SR-B1.

The Gist

The Big Picture: A Sneaky Virus and Its "Trojan Horse"

Imagine the Hepatitis B virus (HBV) as a master thief trying to break into a bank (your liver cells). For years, scientists knew how the thief picked the lock (using a specific key called NTCP), but they didn't know what tools the thief was carrying in their backpack to help them get in.

This paper is like a forensic investigation where scientists finally emptied the thief's backpack, analyzed every item inside, and discovered a surprising secret weapon: a protein called ApoC1.

The Investigation: Cleaning the Crime Scene

To find out what the virus was carrying, the scientists had to be very careful. Usually, when you catch a virus in a lab, it's mixed with a lot of "junk" from the cell culture (like dust and random proteins).

• The Analogy: Imagine trying to find a specific gold coin in a bucket of mud. If you just scoop the mud, you get mud.
• The Solution: The researchers built a high-tech "gold panning" machine. They used a series of filters, magnets, and spinning centrifuges to wash away the mud and isolate only the pure virus particles. This allowed them to see exactly what was stuck to the virus surface.

The Discovery: The "High-Density Lipoprotein" (HDL) Connection

When they looked at the purified virus, they found something unexpected: Apolipoprotein C1 (ApoC1).

• What is ApoC1? Think of ApoC1 as a VIP pass or a "golden ticket" usually found on HDL (High-Density Lipoprotein). In your body, HDL is the "good cholesterol" that acts like a delivery truck, transporting fats and cholesterol around.
• The Twist: The Hepatitis B virus has hijacked this delivery truck. It sticks ApoC1 onto its own surface, effectively disguising itself as a harmless cholesterol delivery truck.

How the Virus Uses This Trick (The Two-Part Strategy)

The paper explains that ApoC1 helps the virus in two clever ways:

1. The "Cholesterol Fuel" Effect

• The Metaphor: Imagine the virus needs a specific type of fuel (cholesterol) to start its engine once it gets inside the cell.
• The Science: ApoC1 helps manage the cell's cholesterol levels. When the virus brings ApoC1 with it, it ensures there is enough "fuel" (cholesterol) right at the door to help the virus merge with the cell and get inside. If you remove ApoC1, the virus runs out of fuel and can't infect the cell.

2. The "VIP Bouncer" Effect

• The Metaphor: The liver cell has a bouncer at the door. Usually, the virus has to show a specific ID (the NTCP receptor) to get in. But with ApoC1 attached, the virus can also show a "VIP pass" to a different bouncer called SR-B1.
• The Science: SR-B1 is a receptor that usually lets HDL (the good cholesterol) into the cell. By wearing the ApoC1 "VIP pass," the virus tricks the SR-B1 bouncer into letting it in, too. It's like the virus is saying, "I'm not a thief; I'm a cholesterol delivery truck!"

The Proof: Blocking the Trick

To prove this theory, the scientists tried two things:

1. The Shield: They used an antibody (a shield) to cover up the ApoC1 on the virus. Result? The virus couldn't get in.
2. The Bouncer: They used a drug to block the SR-B1 bouncer. Result? Even with the VIP pass, the virus was turned away at the door.

They also tested this on Hepatitis D (HDV), a "satellite virus" that needs Hepatitis B to survive. The same trick worked! If you block ApoC1 or SR-B1, HDV is also stopped.

Why This Matters: A New Way to Fight the Virus

Currently, treatments for Hepatitis B suppress the virus but rarely cure it. The virus hides in a "safe house" inside the cell nucleus (cccDNA) that drugs can't reach.

This research suggests a new strategy: Don't just attack the virus; attack its disguise.

• The Future: Since ApoC1 is related to cholesterol, and we already have drugs that lower cholesterol or block cholesterol receptors (like SR-B1 inhibitors), we might be able to repurpose these existing drugs to stop Hepatitis B.
• The Takeaway: By understanding that the virus is "borrowing" our own cholesterol delivery system to get into cells, we can build a roadblock that stops the virus without harming the patient.

Summary in One Sentence

Scientists discovered that the Hepatitis B virus steals a piece of our "good cholesterol" system (ApoC1) to disguise itself as a delivery truck, tricking liver cells into letting it inside; blocking this disguise could be the key to a new cure.

Technical Summary

1. Problem Statement

Chronic Hepatitis B Virus (HBV) infection affects approximately 254 million people globally and is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC). Current antiviral therapies (nucleos(t)ide analogues) suppress viral replication but rarely achieve a functional cure because they do not eliminate the covalently closed circular DNA (cccDNA) reservoir. Furthermore, infected hepatocytes release massive amounts of non-infectious subviral particles (SVPs), which induce immune tolerance.

A critical gap in understanding HBV pathogenesis is the lack of knowledge regarding host cell proteins that are incorporated into HBV virions and SVPs and subsequently delivered into target cells. Identifying these host dependency factors could reveal novel therapeutic targets to block viral entry or production.

2. Methodology

The authors employed a multi-step approach combining advanced biophysics, proteomics, and functional virology:

• Particle Purification Pipeline:
  • Used two cell lines: HepAD38 (produces infectious virions and SVPs) and HepG2-HB2.7 (produces only SVPs).
  • Implemented a sequential purification protocol: Heparin affinity chromatography $\rightarrow$ Size-exclusion chromatography (to separate large particles like virions/filamentous SVPs from spherical SVPs) $\rightarrow$ Density gradient centrifugation.
  • Performed HBsAg-specific immunoprecipitation (IP) to remove contaminating serum proteins and enrich for viral particles prior to mass spectrometry.
• Proteomics Analysis:
  • Utilized Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) to identify proteins associated with purified virions and filamentous SVPs (fSVPs).
  • Applied strict filtering criteria: proteins must be present in $\ge$3 biological replicates and show significant enrichment over IgG controls.
• Functional Screening:
  • Conducted an RNAi-based screen targeting 48 candidate host proteins identified in the proteome.
  • Used HepG2-NTCP A3 cells for HBV infection and Huh7-NTCP cells for Hepatitis D Virus (HDV) infection (as a surrogate for HBV entry).
  • Measured viral markers (HBsAg, HBeAg, HBV DNA, pgRNA, cccDNA) and cytotoxicity.
• Mechanistic Validation:
  • Cholesterol Rescue: Tested if exogenous cholesterol could reverse the effects of ApoC1 depletion.
  • Neutralization Assays: Pre-incubated viral stocks with ApoC1-specific antibodies to test infectivity.
  • Lipoprotein Interaction: Analyzed the association of ApoC1 with HDL and viral particles using Western blot, qPCR, and Transmission Electron Microscopy (TEM) with immunogold labeling.
  • Receptor Studies: Investigated the role of the HDL receptor SR-B1 using siRNA knockdown and pharmacological inhibitors (BLT-1 and BLT-4).

3. Key Contributions

• First High-Resolution HBV Proteome: Established a robust purification pipeline enabling the detection of low-abundance viral proteins (e.g., the P-protein at ~1 copy per virion) and host factors previously undetected in HBV particles.
• Identification of ApoC1: Identified Apolipoprotein C1 (ApoC1) as a critical host factor associated with both HBV virions and fSVPs.
• Dual-Mechanism Discovery: Revealed that ApoC1 promotes HBV infection through two distinct mechanisms:
  1. Intracellular Regulation: Maintaining intracellular cholesterol levels necessary for particle production and entry.
  2. Extracellular Facilitation: Acting as a bridge between the virus and the host cell via HDL and the SR-B1 receptor to enhance infectivity.
• HDV Relevance: Demonstrated that these mechanisms also apply to Hepatitis D Virus (HDV), which relies on the HBV envelope.

4. Key Results

• Proteomic Findings:

  • Identified 168 host proteins enriched in HBV particles.
  • Confirmed known chaperones (HSP90AB1, HSC70) and discovered novel factors, including a cluster of apolipoproteins (ApoA1, ApoA2, ApoC1, ApoC3, ApoE).
  • ApoC1 was the top hit in the functional screen, showing the most consistent and potent reduction in viral replication upon knockdown.

• Functional Validation of ApoC1:

  • Knockdown Effects: Depletion of ApoC1 significantly reduced HBsAg, HBeAg, HBV DNA, pgRNA, and cccDNA levels. It also impaired SVP production in the HB2.7 cell line.
  • Specificity: The effect was specific to ApoC1; ApoE depletion did not compensate for ApoC1 loss, and double knockdown showed no additive effect, suggesting ApoC1 is the dominant factor.
  • Cholesterol Link: ApoC1 knockdown reduced intracellular cholesterol. Supplementing exogenous cholesterol partially rescued HBV replication, indicating ApoC1 supports infection by regulating cellular lipid homeostasis.

• Association with Viral Particles:

  • Immunoprecipitation and TEM confirmed that ApoC1 physically associates with purified HBV virions and fSVPs.
  • ApoC1 was detected in HBV particles isolated from the serum of chronic hepatitis B patients, confirming physiological relevance.
  • TEM revealed HDL-like structures adjacent to viral particles, suggesting ApoC1 is carried on HDL.

• Entry Mechanism (SR-B1 Dependence):

  • Neutralization: Pre-incubating HBV with anti-ApoC1 antibodies reduced infectivity, proving ApoC1 on the virion surface aids entry.
  • HDL Enhancement: Adding exogenous HDL to infection assays increased HBV infectivity.
  • SR-B1 Role: Knockdown of Scavenger Receptor Class B Type 1 (SR-B1) significantly reduced HBV and HDV infection. Pharmacological inhibition of SR-B1 (using BLT-1/4) suppressed viral entry in both cell lines and Primary Human Hepatocytes (PHHs).
  • NTCP Independence: ApoC1 depletion did not affect the surface abundance of NTCP (the primary HBV receptor), indicating ApoC1 acts as a co-factor facilitating entry after initial attachment or via a distinct pathway involving SR-B1.

5. Significance

• Therapeutic Implications: The study identifies ApoC1 and SR-B1 as novel therapeutic targets. Since SR-B1 inhibitors (BLT compounds) effectively blocked HBV/HDV entry in primary human hepatocytes, repurposing existing lipid-modulating drugs could be a viable strategy for a functional cure.
• Mechanistic Insight: The findings challenge the view that HBV entry is solely dependent on NTCP. Instead, they propose a model where HBV "hijacks" the host's reverse cholesterol transport pathway, utilizing ApoC1 and HDL to target SR-B1, thereby facilitating efficient entry and potentially evading immune detection.
• Broad Applicability: The dual role of ApoC1 (intracellular cholesterol regulation and extracellular entry facilitation) offers a comprehensive explanation for its critical role in the HBV life cycle, bridging the gap between viral production and infection.

In conclusion, this paper provides a high-resolution map of the HBV proteome and uncovers a critical host-virus interaction axis involving ApoC1, HDL, and SR-B1, offering new avenues for antiviral drug development.